By Olivia Bugault

Fresenius SE & Co. said Thursday that its Kabi unit and German pharmaceutical company medac have entered into a marketing agreement for treatments of rheumatic illnesses.

"On June 1, medac's sales representatives will begin offering the adalimumab biosimilar IDACIO(R) as an additional therapy option to the rheumatologists and dermatologists they work with," the German health-care company said.

The product developed by Fresenius Kabi was launched in Europe in 2019 for the treatment of illnesses such as arthritis and psoriasis, it said.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

May 28, 2020 03:07 ET (07:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Fresenius SE and Company... (PK) (USOTC:FSNUY)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Fresenius SE and Company... (PK) Charts.
Fresenius SE and Company... (PK) (USOTC:FSNUY)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Fresenius SE and Company... (PK) Charts.